Dr. Khan is a virologist with extensive experience in cell and molecular biology. His research experience encompasses numerous fields of virology with special emphasis on viral immunology, antiviral research, vaccines, and pathogenesis. He obtained his Ph.D. in 2011 from Jiwaji University, India, working on prophylactic and therapeutic measures against tropical arboviruses such as Dengue and Chikungunya. He then joined the department of medicine, UC, San Diego as a postdoctoral researcher, where he primarily focused on identifying novel mechanistic insights and therapeutic targets of HBV and HCV induced hepatitis. In 2016, he was promoted as Project Scientist and served as a co-investigator for an NIH-funded R01 grant. He has > 25 research articles to his credit and serves as an invited referee for several articles submitted to leading journals in the field of virology. His long term career goal is to develop novel therapeutic strategies for the treatment of chronic liver diseases and viral hepatitis.
Dr. Joselyn N. Allen graduated from the University of the Virgin Islands in 2010, where she earned her Bachelor of Science in General Biology. She obtained her Ph.D. degree in Immunology and Infectious Diseases in 2018 from the Pennsylvania State University. Her current research focuses on the role of the Mir122 - Map3k14 axis in the development and progression of non-alcoholic fatty liver disease, as well as the role of the bile acid - gut microbiome axis in age-dependent HBV clearance.
Sai Teja Bondalapati graduated from Columbia University with a BA in Biochemistry. His current research in the Liver Diseases Branch at NIDDK focuses on crystallization of HBx, a transactivating protein known to alleviate transcription repression via directing Smc5/6 for ubiquitination and further degradation.
Dr. Inuzuka obtained his MD from Kyoto University in 2006. He then received a clinical training as an intern at Kyoto University Hospital and Osaka Red Cross Hospital. He worked as a Physician in Gastroenterology and Hepatology at Osaka Red Cross Hospital for 4 years. He received basic research training in molecular and cell biology and virology at Kyoto University, where he obtained his Ph.D. in 2016. After winning a Japan Society for the Promotion of Science scholarship, Dr. Inuzuka spent 2 years as a postdoc fellow at National Center for Global Health and Medicine in Japan working on investigation of the relationship between genetic changes and pathogenesis of hepatitis B virus. From 2018, he has worked with Dr. T. Jake Liang at the Liver Diseases Branch of NIDDK, NIH. Dr. Inuzuka’s current research at NIH focuses on understanding host factors associated with hepatitis B virus infection.
Parker Irvin graduated from the University of North Florida in August 2019 with a BS in Molecular & Cell Biology. His current research involves the identification and characterization of SARS CoV-2 antivirals and mapping novel epitopes on HCV envelope proteins.
Madeleine Leek graduated from the University of Pittsburgh with a BS in Emergency Medicine. She worked as a paramedic in east Pittsburgh and in the liver research center at the McGowan Institute for Regenerative Medicine. Her current research in the Liver Disease Branch at NIDDK involves the role of the host microbiome and bile acids in age and strain related clearance of HBV.
Dr. Karim Mouzannar started his scientific journey at Université Saint-Joseph in Lebanon with a B.S. in Biochemistry. He then traveled to Paris and earned a M.S. in Molecular and Cellular Biology from Université Pierre et Marie Curie. Afterwards, he went to the infectiology research hub of Lyon and pursued a PhD. in Virology from Université Claude Bernard. His work identified the bile acid nuclear receptor, FXR alpha, as a proviral host factor for Hepatitis B Virus that is inhibited by ligands in vitro and in vivo. Subsequently, he traveled to the US and joined Dr. Jake Liang’s team at the NIH to pursue his work on HBV therapeutic development.
Dr. Seung Bum Park graduated from Yonsei University with a B.Sc in biotechnology in February 2005, University of California, Davis with a M.Sc in immunology in June 2006, and University of California, Merced with a Ph.D in immunology/virology in August 2015. His current research is to study differentiation of induced pluripotent stem cells/embryonic stem cells into hepatocytes.
Samantha Tilson graduated summa cum laude from the University of Alabama with a B.S. in Chemical Engineering and a minor in undergraduate research in 2016. She is currently in her final year in the NIH Oxford Cambridge Scholars (OxCam) Program. Her collaborative Ph.D. project has been performed in the laboratories of Dr. T. Jake Liang in the Liver Disease Branch at NIDDK and Dr. Ludovic Vallier in the Wellcome Sanger Institute at the University of Cambridge. Her research focuses on exploring the genetic determinants of non-alcoholic fatty liver disease (NAFLD). Specifically, she has created an in vitro model system to study how genetic variations in the PNPLA3 gene contribute to the development and progression of NAFLD using human induced pluripotent stem cells (hiPSCs) and the CRISPR/CAS9 gene editing technology.
Dr. Uchida graduated from Oita University, Japan and obtained MD in 2009. After fellowship in gastroenterology and hepatology, he obtained PhD at Hiroshima University in 2017. He continued basic research after the graduate school and investigated virology and immunology of hepatitis viruses (mainly HBV and HCV) using human hepatocyte chimeric mouse model in Hiroshima University. He is an assistant professor of Department of Gastroenterology and Metabolism, Hiroshima University from 2018. He is working on CRISPR base editing project and trying to generate the mouse model using stem cell derived hepatocyte like cells.
Dr. Zhang’s research focuses on the liver diseases in virology, immunology, cell biology, and therapeutics. She is conducting her current research in the Liver Disease Branch of NIDDK from 2016. Her research involves developing and exploring different genotypes HBV. She also learn to do some research on screening HBV drugs.
Ms. Regina Umarova graduated from New Mexico Highlands University with a B.S. in biology in 2014, and University of Texas at El Paso with a M.S. in bioinformatics in 2018. She joined LDB-NIDDK in February 2019 as a Bioinformatics Analyst.